An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Academic rigor, journalistic flair
Articles on Alzheimer's disease
Displaying 61 - 80 of 346 articles
The decision to move a loved one with dementia into residential care is an incredibly difficult one. These considerations may help.
Not all memory lapses are due to age-related changes in our brains. You could just be tired, anxious or distracted. Here’s what signals a problem.
Impaired insulin receptors in the blood vessels between the blood and the brain may contribute to the insulin resistance observed in Alzheimer’s disease.
Two new dementia drugs are being hailed as breakthroughs. But what might be an incremental breakthrough for researchers, doesn’t mean a cure for patients.
Microglia, immune cells disguised as brain cells, are known as the janitors of the brain. Dialing up their usual duties just enough could provide an avenue to treat neurodegenerative disease.
Lecanemab slows progression of early-stage Alzheimer’s disease in some, new study shows. But the ‘adverse events’ are significant.
With a good diet and rest, we can all reduce our risk of dementia.
Experimental drugs gantenerumab has failed phase 3 clinical trials. Here’s what that means for the future of the amyloid hypothesis.
The world’s longest running cohort study reveals risk factors for dementia. Families of athletes with early-onset dementia tell their stories. Could viruses cause Alzheimer’s? Listen to the Uncharted Brain: Decoding Dementia podcast series.
Listen to the third episode of our series Uncharted Brain: Decoding Dementia via The Anthill podcast.
Listen to the first episode of our series Uncharted Brain: Decoding Dementia via The Anthill podcast.
Ruth Itzhaki has spent more than 30 years researching whether certain common viruses play a role in the development of Alzheimer’s. But for years her research was greeted with hostility.
Just months after the end of the second world war, the longest running study of health over the human life course in the world began – and it’s still going.
With an increasing number of people living with dementia worldwide and in Canada, it’s crucial to find ways to promote community awareness and prevent people with dementia from getting lost.
A podcast and long read series exploring new research into the brain and dementia.
Too much amyloid-beta in the brain has long been considered the cause of Alzheimer’s. New research suggests it might be the opposite.
Lecanemab, an experimental dementia drug, slowed cognitive decline by 27% in late-stage clinical trials.
Here’s why it’s so important to look after your oral health.
New study finds that middle-aged people who had nightmares every week, are four times more likely to experience cognitive decline.
Top contributors
-
Research Fellow in Neuroimmunology, UCL
-
Associate Professor, Turner Institute for Brain and Mental Health, Monash University
-
Professor of Neurology and Neuroscience, University of Florida
-
Professor Emeritus of Molecular Neurobiology at the University of Manchester and a Visiting Professorial Fellow, University of Oxford
-
Professor of Neurology, UCL
-
Professor of Psychology in Epidemiology, UCL
-
Post grad student at University of Edinburgh, The University of Edinburgh
-
Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
-
Professor of Chemistry and Senior Scientist of the Krembil Research Institute, University Health Network, University of Toronto
-
Associate Professor in Cellular Neuroscience, University of Reading
-
Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
-
Investigations Editor, Insights, The Conversation
-
Associate Professor of Medicine and Geriatrics, University of Virginia
-
Editor and Co-Host, The Conversation Weekly Podcast, The Conversation
-
Postdoctoral Research Fellow, Tufts University
